Company news
Island Pharmaceuticals Ltd news in 2023
Island Pharmaceuticals Ltd's news releases, calls and decks from 2023, newest first.
Approval to commence dosing 3rd cohort of ISLA-101 SAD study
December 21, 2023
R&D Tax Incentive loan facility secured with Radium Capital
December 14, 2023
Second cohort dosed in ISLA-101 Single Ascending Dose study
December 11, 2023
Island doses first cohort in ISLA-101 clinical trial
November 24, 2023
Screening commences for ISLA-101 Single Ascending Dose Study
November 12, 2023
Island receives R&D tax refund for FY2023
November 9, 2023
Island receives ethics approval for ISLA-101 study
November 6, 2023
ILA granted key Australian patent for ISLA-101
November 1, 2023
Quarterly Activity Report & Appendix 4C
October 29, 2023
ISLA-101 Single Ascending Dose study update
September 24, 2023
Island Pharmaceuticals granted key U.S. patent for ISLA-101
September 12, 2023
Appendix 4E & Annual Report
August 30, 2023
US grant funding to support ISLA-101 clinical development
July 6, 2023
Island receives FDA go-ahead for ISLA-101 program
May 15, 2023
Island submits responses to FDA questions for ISLA-101
April 16, 2023
ILA receives additional FDA feedback on IND for ISLA 101
January 31, 2023
Island receives FDA feedback on Phase 2a clinical study
January 19, 2023
Decks in 2023
- Shareholder Meeting (November 2023)
Shareholder meeting · 24 slides · Nov 16, 2023
- Investor Presentation (November 2023)
Investor deck · 25 slides · Nov 6, 2023